Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1976 Jun;9(6):915–919. doi: 10.1128/aac.9.6.915

Activity of Amphotericin B, 5-Fluorocytosine, and Rifampin Against Six Clinical Isolates of Aspergillus

M Kitahara 1, V K Seth 1, G Medoff 1, G S Kobayashi 1
PMCID: PMC429650  PMID: 820247

Abstract

Amphotericin B in combination with 5-fluorocytosine was synergistic against three clinical isolates of Aspergillus fumigatus and one of three clinical isolates of A. flavus. Amphotericin B in combination with rifampin was synergistic against all six clinical isolates of Aspergillus tested. The levels of 5-fluorocytosine and rifampin required for synergism were higher than clinically achievable concentrations when measurements of synergism were based on visual turbidity; but when the effects of the drugs were measured by inhibition of ribonucleic acid synthesis or dry-weight increase, much lower concentrations were effective.

Full text

PDF
915

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Block E. R., Bennett J. E. The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis. Proc Soc Exp Biol Med. 1973 Feb;142(2):476–480. doi: 10.3181/00379727-142-37049. [DOI] [PubMed] [Google Scholar]
  2. Carrizosa J., Levison M. E., Lawrence T., Kaye D. Cure of Aspergillus ustus endocarditis on a prosthetic valve. Arch Intern Med. 1974 Mar;133(3):486–490. [PubMed] [Google Scholar]
  3. Cheung S. S., Kobayashi G. S., Schlessinger D., Medoff G. RNA metabolism during morphogenesis in Histoplasma capsulatum. J Gen Microbiol. 1974 Jun;82(2):301–307. doi: 10.1099/00221287-82-2-301. [DOI] [PubMed] [Google Scholar]
  4. Drutz D. J., Spickard A., Rogers D. E., Koenig M. G. Treatment of disseminated mycotic infectioons. A new approach to amphotericin B therapy. Am J Med. 1968 Sep;45(3):405–418. doi: 10.1016/0002-9343(68)90075-2. [DOI] [PubMed] [Google Scholar]
  5. Kitahara M., Seth V. K., Medoff G., Kobayashi G. S. Antimicrobial susceptibility testing of six clinical isolates of Aspergillus. Antimicrob Agents Chemother. 1976 Jun;9(6):908–914. doi: 10.1128/aac.9.6.908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kobbayashi G. S., Medoff G., Schlessinger D., Kwan C. N., Musser W. E. Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum. Science. 1972 Aug 25;177(4050):709–710. doi: 10.1126/science.177.4050.709. [DOI] [PubMed] [Google Scholar]
  7. Medoff G., Comfort M., Kobayashi G. S. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc Soc Exp Biol Med. 1971 Nov;138(2):571–574. doi: 10.3181/00379727-138-35943. [DOI] [PubMed] [Google Scholar]
  8. Medoff G., Kobayashi G. S., Kwan C. N., Schlessinger D., Venkov P. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism). Proc Natl Acad Sci U S A. 1972 Jan;69(1):196–199. doi: 10.1073/pnas.69.1.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Rabinovich S., Shaw B. D., Bryant T., Donta S. T. Effect of 5-fluorocytosine and amphotericin B on Candida albicans infection in mice. J Infect Dis. 1974 Jul;130(1):28–31. doi: 10.1093/infdis/130.1.28. [DOI] [PubMed] [Google Scholar]
  10. SALVIN S. B. Growth of the yeastlike phase of Histoplasma capsulatum in a fluid medium. J Bacteriol. 1950 Feb;59(2):312–313. doi: 10.1128/jb.59.2.312-313.1950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Titsworth E., Grunberg E. Chemotherapeutic activity of 5-fluorocytosine and amphotericin B against Candida albicans in mice. Antimicrob Agents Chemother. 1973 Sep;4(3):306–308. doi: 10.1128/aac.4.3.306. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES